RU2015148769A - Медицинское применение синдекана-2 - Google Patents
Медицинское применение синдекана-2 Download PDFInfo
- Publication number
- RU2015148769A RU2015148769A RU2015148769A RU2015148769A RU2015148769A RU 2015148769 A RU2015148769 A RU 2015148769A RU 2015148769 A RU2015148769 A RU 2015148769A RU 2015148769 A RU2015148769 A RU 2015148769A RU 2015148769 A RU2015148769 A RU 2015148769A
- Authority
- RU
- Russia
- Prior art keywords
- sdc2
- fragments
- use according
- surface protein
- compound
- Prior art date
Links
- 102000003711 Syndecan-2 Human genes 0.000 title 1
- 108090000054 Syndecan-2 Proteins 0.000 title 1
- 101000692109 Homo sapiens Syndecan-2 Proteins 0.000 claims 53
- 102100026087 Syndecan-2 Human genes 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 13
- 102000018697 Membrane Proteins Human genes 0.000 claims 11
- 108010052285 Membrane Proteins Proteins 0.000 claims 11
- 206010062016 Immunosuppression Diseases 0.000 claims 6
- 230000001506 immunosuppresive effect Effects 0.000 claims 6
- 230000037361 pathway Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 3
- 102000050970 human SDC2 Human genes 0.000 claims 2
- 108010059616 Activins Proteins 0.000 claims 1
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 101100256304 Caenorhabditis elegans sdc-2 gene Proteins 0.000 claims 1
- 101000994439 Danio rerio Protein jagged-1a Proteins 0.000 claims 1
- 102100036462 Delta-like protein 1 Human genes 0.000 claims 1
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 1
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 241000027355 Ferocactus setispinus Species 0.000 claims 1
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 claims 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 claims 1
- 102000014736 Notch Human genes 0.000 claims 1
- 108010070047 Notch Receptors Proteins 0.000 claims 1
- 102100032702 Protein jagged-1 Human genes 0.000 claims 1
- 102100032733 Protein jagged-2 Human genes 0.000 claims 1
- 101710170213 Protein jagged-2 Proteins 0.000 claims 1
- 102000013814 Wnt Human genes 0.000 claims 1
- 101100499376 Xenopus laevis dll2 gene Proteins 0.000 claims 1
- 239000000488 activin Substances 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (20)
1. SDC2, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2 или композиции, содержащие SDC2, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2, при этом фрагмент, вариант или белок типа SDC-2 обладает активностью SDC2, для применения в иммуносупрессии.
2. Растворимый SDC2, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2 или композиции, содержащие растворимый SDC2, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2 для применения по п. 1.
3. SDC2 человека, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2 или композиции, содержащие SDC2, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2 для применения по п. 1.
4. SDC2, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2 или композиции, содержащие SDC2, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2 для применения по п. 1, в котором SDC2 получен из супернатанта культуры клеток.
5. Вектор, кодирующий SDC2, фрагменты SDC2 или активные варианты SDC2 для применения в иммуносупрессии.
6. Вектор для применения по п. 5, кодирующий SDC2 человека.
7. Соединение, которое модулирует экспрессию SDC2 для применения в иммуносупрессии.
8. Соединение для применения по п. 6, которое увеличивает экспрессию SDC2.
9. Соединение для применения по п. 8, выбранное из соединений, которые активируют p53.
10. Соединение для применения по п. 8, выбранное из соединений, которые активируют пути киназ ERK, p38 или JNK SAPK.
11. Соединение для применения по п. 8, выбранное из соединений, которые активируют путь, опосредованный индуцируемым гипоксией фактором (HIF).
12. Соединение для применения по п. 8, выбранное из соединений, которые агонизируют пути TGF, BMP, Lefty, Nodal и активина.
13. Соединение для применения по п. 8, выбранное из соединений, которые агонизируют путь NOTCH, например Jagged1, Jagged2, DLL1, DLL2, DLL3 и DLL4.
14. Соединение для применения по п. 8, выбранное из соединений, которые агонизируют путь передачи сигнала Hedgehog.
15. Соединение для применения по п. 8, выбранное из соединений, которые агонизируют путь WNT.
16. Соединение для применения по п. 8, выбранное из соединений, которые активируют путь рецептора андрогена или рецептора эстрогена.
17. Клетки или ткань в комбинации с SDC2, фрагментами SDC2, активными вариантами SDC2 или поверхностным белком типа SDC2 или композициями, содержащими SDC2, фрагменты SDC2, активные варианты SDC2 или поверхностный белок типа SDC2, по п.1., или обработанные векторами по п.5 или соединениями по п.7, для применения в иммуносупрессии.
18. Антитело к SDC2 для применения в терапии человека.
19. Антитело к SDC2 для применения в иммуносупрессии.
20. Способ лечения пациента для того, чтобы вызвать иммуносупрессию, включающий введение пациенту SDC2, фрагментов SDC2, активных вариантов SDC2 или поверхностного белка типа SDC2 или антитела к SDC2.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201306886A GB201306886D0 (en) | 2013-04-16 | 2013-04-16 | Immuno-modulatory and angiopoletic agents and compositions, and uses theereof |
| GB1306886.1 | 2013-04-16 | ||
| GB1314544.6 | 2013-08-14 | ||
| GB201314544A GB201314544D0 (en) | 2013-08-14 | 2013-08-14 | Immuno-modulatory and angiopoietic agents and compositions, and uses thereof |
| PCT/EP2014/057830 WO2014170411A1 (en) | 2013-04-16 | 2014-04-16 | Medical use of syndecan-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015148769A true RU2015148769A (ru) | 2017-05-23 |
| RU2015148769A3 RU2015148769A3 (ru) | 2018-03-20 |
Family
ID=50513926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015148769A RU2015148769A (ru) | 2013-04-16 | 2014-04-16 | Медицинское применение синдекана-2 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10251934B2 (ru) |
| EP (1) | EP2986631B1 (ru) |
| JP (1) | JP6438457B2 (ru) |
| KR (2) | KR102480812B1 (ru) |
| CN (1) | CN105324391A (ru) |
| AU (1) | AU2014255755B2 (ru) |
| BR (1) | BR112015026258A2 (ru) |
| CA (2) | CA3205855A1 (ru) |
| RU (1) | RU2015148769A (ru) |
| WO (1) | WO2014170411A1 (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
| SG173492A1 (en) | 2009-02-03 | 2011-09-29 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising said stem cells. |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| KR102480812B1 (ko) | 2013-04-16 | 2022-12-22 | 오르브센 테라퓨틱스 리미티드 | 신데칸 2의 의학적 용도 |
| AU2015261380B2 (en) | 2014-05-16 | 2021-04-15 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved culture method for organoids |
| GB201421092D0 (en) * | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| GB201421094D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| US10124038B2 (en) | 2015-03-20 | 2018-11-13 | Orbsen Therapeutics Limited | Modulators of syndecan-2 and uses thereof |
| US11918687B2 (en) * | 2016-01-15 | 2024-03-05 | Orbsen Therapeutics Limited | SDC-2 exosome compositions and methods of isolation and use |
| GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
| US11517545B2 (en) | 2016-12-15 | 2022-12-06 | Evoke Pharma, Inc. | Treatment of moderate and severe gastroparesis |
| WO2018220442A2 (en) * | 2017-05-30 | 2018-12-06 | Orbsen Therapeutics Limited | Stromal stem cell therapeutics and methods of use |
| KR102722188B1 (ko) * | 2017-07-14 | 2024-10-24 | 오르브센 테라퓨틱스 리미티드 | 씨디39 기질 줄기세포 단리 방법 및 용도 |
| CN108251359B (zh) * | 2017-12-20 | 2021-07-09 | 上海华新生物高技术有限公司 | 一种间充质干细胞无血清培养基及培养方法 |
| GB201819224D0 (en) | 2018-11-26 | 2019-01-09 | Koninklijke Nederlandse Akademie Van Wetenschappen | Hepatocyte expansion methods |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| JP2023537452A (ja) * | 2020-05-22 | 2023-09-01 | イエール ユニバーシティ | 血管漏出を処置するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN111979186B (zh) * | 2020-08-21 | 2022-04-08 | 遵义医科大学附属医院 | 一种快速高效体外扩增人间充质干细胞的方法及应用 |
| CN111979187B (zh) * | 2020-08-21 | 2022-04-08 | 遵义医科大学附属医院 | 一种抗人间充质干细胞衰老及增强其干性特征的方法 |
| WO2022179518A1 (en) * | 2021-02-25 | 2022-09-01 | Rosas Ivan O | Anti-fibrotic peptides and uses thereof |
| CN119372206A (zh) * | 2024-12-30 | 2025-01-28 | 崖州湾国家实验室 | 一种蛋白聚糖基因在抗非洲猪瘟病毒感染中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486599A (en) | 1989-03-29 | 1996-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Construction and use of synthetic constructs encoding syndecan |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5726058A (en) | 1992-12-01 | 1998-03-10 | Jalkanen; Markku | Syndecan stimulation of cellular differentiation |
| CA2323073C (en) | 1998-03-13 | 2010-06-22 | Osiris Therapeutics, Inc. | Uses for human non-autologous mesenchymal stem cells |
| US7442390B2 (en) | 2000-06-05 | 2008-10-28 | University Of South Florida | Method for enhancing engraftment of cells using mesenchymal progenitor cells |
| WO2002087609A1 (en) | 2001-05-01 | 2002-11-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Identification of a cell surface receptor for papillomaviruses |
| AU2002360424A1 (en) | 2001-11-26 | 2003-06-10 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| WO2003062386A2 (en) | 2002-01-18 | 2003-07-31 | Regents Of The University Of Minnesota | Syndecans and angiogenesis |
| EP1539931A4 (en) * | 2002-06-27 | 2006-08-23 | Univ Queensland | DIFFERENTIATING MODULATING AGENTS AND USES THEREFOR |
| EP1583422B1 (en) | 2002-12-05 | 2016-03-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| EP1789534B1 (en) | 2004-08-16 | 2014-08-06 | CellResearch Corporation Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
| EP1795588A1 (en) | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
| WO2007122823A1 (ja) | 2006-04-20 | 2007-11-01 | Jichi Medical University | ベクター産生型腫瘍標的細胞 |
| US20070264239A1 (en) | 2006-05-10 | 2007-11-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Isolation of pericytes |
| WO2008085229A2 (en) | 2006-11-15 | 2008-07-17 | Arteriocyte Inc. | Cell-based therapies for treating liver disease |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| KR100883565B1 (ko) | 2007-02-14 | 2009-02-13 | (주)프로스테믹스 | 지방 줄기세포의 조직 재생 능력을 최적화한 조건 배지를 함유한 조직 재생용 주사제 첨가제 |
| US20100111914A1 (en) | 2007-05-21 | 2010-05-06 | Yuanyuan Zhang | Stem cells from urine and methods for using the same |
| EP2676678A1 (en) | 2007-07-17 | 2013-12-25 | The General Hospital Corporation | Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof |
| CN101835889B (zh) | 2007-10-17 | 2013-07-17 | 特克赛尔公司 | Tr1细胞、间充质干细胞和其用途 |
| US20090220588A1 (en) | 2008-02-21 | 2009-09-03 | Massachusetts Institute Of Technology | Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity |
| KR20100106744A (ko) | 2009-03-24 | 2010-10-04 | 이화여자대학교 산학협력단 | 이동성 피부세포질환 또는 멜라닌 합성관련 질환 예방 또는치료용 조성물 |
| KR101301262B1 (ko) | 2009-10-23 | 2013-08-27 | 가톨릭대학교 산학협력단 | ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도 |
| KR101622650B1 (ko) | 2009-12-31 | 2016-06-01 | 엘지디스플레이 주식회사 | 액정 전계 렌즈 및 이를 이용한 입체 표시 장치 |
| CA2792802C (en) | 2010-03-10 | 2017-10-31 | Two Cells Co., Ltd. | Cell preparation containing mesenchymal stem cells, and method for producing same |
| WO2011153458A2 (en) | 2010-06-03 | 2011-12-08 | University Of Rochester | Compositions and methods for inhibition of or treatment of dengue virus infection |
| KR101309910B1 (ko) | 2010-08-06 | 2013-09-17 | 이화여자대학교 산학협력단 | 대장암 진단 및 치료제로서의 신데칸-2 펩티드 단편 |
| KR101317507B1 (ko) | 2010-08-30 | 2013-10-15 | 가톨릭대학교 산학협력단 | 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물 |
| KR20120095022A (ko) | 2011-02-18 | 2012-08-28 | 가톨릭대학교 산학협력단 | 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물 |
| KR101284277B1 (ko) | 2011-07-15 | 2013-07-08 | 한림대학교 산학협력단 | 항염증 활성을 나타내는 청시닥 나무 수피 추출물 및 이를 함유하는 조성물 |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2013134649A1 (en) | 2012-03-09 | 2013-09-12 | Verastem, Inc. | Biomarkers for cancer stem cells and related methods of use |
| EP2850178A4 (en) | 2012-05-18 | 2015-10-28 | Agency Science Tech & Res | EXOSOMES OF MESHCHYMIC STROKE CELL OF UMBILICAL CORD |
| SG11201508433TA (en) | 2013-04-12 | 2015-11-27 | Andaloussi Samir El | Therapeutic delivery vesicles |
| KR102480812B1 (ko) | 2013-04-16 | 2022-12-22 | 오르브센 테라퓨틱스 리미티드 | 신데칸 2의 의학적 용도 |
| SG11201601939VA (en) | 2013-09-16 | 2016-04-28 | Agency Science Tech & Res | Method |
| GB201418562D0 (en) | 2014-10-20 | 2014-12-03 | Univ London Queen Mary | Peptides |
| US10124038B2 (en) | 2015-03-20 | 2018-11-13 | Orbsen Therapeutics Limited | Modulators of syndecan-2 and uses thereof |
| US11918687B2 (en) | 2016-01-15 | 2024-03-05 | Orbsen Therapeutics Limited | SDC-2 exosome compositions and methods of isolation and use |
| WO2018220442A2 (en) | 2017-05-30 | 2018-12-06 | Orbsen Therapeutics Limited | Stromal stem cell therapeutics and methods of use |
-
2014
- 2014-04-16 KR KR1020227014712A patent/KR102480812B1/ko active Active
- 2014-04-16 RU RU2015148769A patent/RU2015148769A/ru not_active Application Discontinuation
- 2014-04-16 EP EP14718403.0A patent/EP2986631B1/en active Active
- 2014-04-16 AU AU2014255755A patent/AU2014255755B2/en active Active
- 2014-04-16 WO PCT/EP2014/057830 patent/WO2014170411A1/en not_active Ceased
- 2014-04-16 BR BR112015026258A patent/BR112015026258A2/pt not_active Application Discontinuation
- 2014-04-16 JP JP2016508166A patent/JP6438457B2/ja active Active
- 2014-04-16 US US14/785,001 patent/US10251934B2/en active Active
- 2014-04-16 CN CN201480025184.5A patent/CN105324391A/zh active Pending
- 2014-04-16 KR KR1020157032129A patent/KR20150143625A/ko not_active Ceased
- 2014-04-16 CA CA3205855A patent/CA3205855A1/en active Pending
- 2014-04-16 CA CA2909356A patent/CA2909356C/en active Active
-
2019
- 2019-01-22 US US16/254,378 patent/US11026994B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014255755B2 (en) | 2018-10-25 |
| RU2015148769A3 (ru) | 2018-03-20 |
| CA2909356A1 (en) | 2014-10-23 |
| US20160058832A1 (en) | 2016-03-03 |
| CN105324391A (zh) | 2016-02-10 |
| JP2016516797A (ja) | 2016-06-09 |
| KR102480812B1 (ko) | 2022-12-22 |
| CA2909356C (en) | 2023-09-12 |
| AU2014255755A1 (en) | 2015-10-08 |
| BR112015026258A2 (pt) | 2017-10-10 |
| JP6438457B2 (ja) | 2018-12-12 |
| WO2014170411A1 (en) | 2014-10-23 |
| EP2986631B1 (en) | 2020-07-29 |
| CA3205855A1 (en) | 2014-10-23 |
| US11026994B2 (en) | 2021-06-08 |
| KR20220062677A (ko) | 2022-05-17 |
| KR20150143625A (ko) | 2015-12-23 |
| EP2986631A1 (en) | 2016-02-24 |
| US10251934B2 (en) | 2019-04-09 |
| US20190365851A1 (en) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015148769A (ru) | Медицинское применение синдекана-2 | |
| IL281484B (en) | A pharmaceutical composition for use in the treatment of a multiple myeloma or a non-hodgkin's lymphoma, the composition comprising human immune effector cells comprising a lentiviral vector expressing a chimeric antigen receptor | |
| BR112017010141A2 (pt) | Forma cristalina de hidrogenossulfato de (s)-n-(5- ((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5- a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida | |
| WO2013173129A3 (en) | Treatment of amd using aav sflt-1 | |
| BR112019008975A2 (pt) | variantes de superfície celular imunologicamente discerníveis para uso em terapia celular | |
| EA201591198A1 (ru) | Антитела к gdf15 | |
| EA201391682A1 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| DK2210588T3 (da) | Opskummelig sammensætning, der er i alt væsentligt fri for farmaceutiske aktive indholdsstoffer, til behandling af menneskehud | |
| WO2013169864A3 (en) | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE | |
| EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| BR112015002152A2 (pt) | pirróis substituídos ativos como inibidores de quinases | |
| EP4592391A3 (en) | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer | |
| EA201791018A1 (ru) | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы | |
| EA201391786A1 (ru) | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| WO2011088120A8 (en) | Antibody formulation and therapeutic regimens | |
| IL240283A (en) | Topical veterinary compositions comprising an isoxazoline active agent, methods and uses thereof for treating or preventing a parasitic infection or infestation in a mammal | |
| EA201790951A1 (ru) | Производные гидроксиалкилзамещенного фенилтриазола и их применение | |
| WO2017151971A3 (en) | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | |
| EA201692007A1 (ru) | Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений | |
| WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
| EA201790950A1 (ru) | Способы и композиции, в частности, для лечения синдрома дефицита внимания | |
| PH12014501613A1 (en) | Anti-asic1 antibodies and uses thereof | |
| MX2016007989A (es) | Derivados de oxindol, preparacion de los mismos y uso terapeutico en el tratamiento de enfermedades relacionadas con ampk. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190115 |